Announced
Completed
Financials
Tags
Friendly
Single Bidder
clinical stage biotechnology
biotechnology company
Majority
Acquisition
United States
Private
De-SPAC
Reverse Takeover
Biotechnology
Domestic
Merger
Failed
Synopsis
APRINOIA Therapeutics, a clinical-stage biotechnology company focused on neurodegenerative diseases, and Ross Acquisition II, a special purpose acquisition company, mutually terminated the $280m merger. The parties entered into a Termination Agreement on August 21, 2023, which is effective immediately and contains mutual releases for claims and liabilities.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.